Pharma stock jumps 10% after signing distribution agreement for 3 products in European marketPharma stock jumps 10% after signing distribution agreement for 3 products in European market

Introduction:

Leading pharma company has entered into a distribution agreement with Denmark-based XGX Pharma to supply three key pharmaceutical products in the European market, including two oncology treatments and one beta-lactam antibiotic formulation.

Also Read: Realty stock jumps after company achieves pre-sales guidance for FY25 with 34% YoY growth

Share price movement of Medicamen Biotech:

On April 8, 2025, Medicamen Biotech Ltd opened at ₹470.95, up 2.22% from its previous close of ₹460.70. The stock touched a high of ₹510.00 (10.66%) and a low of ₹462.50. By 2:08 PM, it traded at ₹495.00, a 7.45% increase, with a market cap of ₹629.37 crore.

Medicamen Biotech Signs Distribution Agreement with XGX Pharma:

Medicamen Biotech Limited has entered into a distribution agreement with Denmark-based XGX Pharma for three pharmaceutical products intended for the European market. The agreement includes both oncology and beta-lactam category medicines.

Medicamen will retain marketing authorization rights for all three products. The oncology products include Temozolamide 250 mg capsules and Bortezomib 3.5 mg injection. The beta-lactam product is Amoxicillin oral dispersible tablets, 250 mg.

This strategic partnership expands Medicamen’s footprint in the European region. The company aims to strengthen its international presence, especially in critical therapeutic segments like oncology and antibiotics, through such collaborations.

Ace investor holding in Medicamen Biotech:

Ashish Chugh

Ashish Chugh holds 135,171 shares, representing a 1.06% stake in Medicamen Biotech Ltd, with his total holding valued at approximately ₹6.7 crore as of the latest data.

Stock performance of Medicamen Biotech for Period of 1 week, 6 months, and 1 year:

Medicamen Biotech Ltd delivered a -7.17% return over the past week and declined by 19.6% in the past six months. The stock gained 5.12% over the past year.

Also Read: Pharma stock jumps 7% after it secures patent for diabetic neuropathic pain

Shareholding pattern of Medicamen Biotech:

Particulars	Dec 2024	Sep 2024	Jun 2024
Promoter	43.00%	43.00%	43.00%
FII	0.10%	0.10%	0.10%
DII	0.90%	1.20%	1.20%
Public	56.00%	55.80%	55.80%

About Medicamen Biotech:

Medicamen Biotech Ltd (NSE: MEDICAMEQ), founded in 1993, is a research-driven pharma company specializing in generic and oncology formulations, supplying to institutional markets and exporting beta-lactam, non-beta-lactam, and cephalosporin drugs.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.